A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days

Summary

To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.

Timeline

Start

—

Primary completion

—

Completion

—

Publications

• Background Eckhardt SG, et al. Results of a phase I trial of the novel angiogenesis inhibitor, tecogalan sodium (meeting abstract). Proc Annu Meet Am Assoc Cancer Res. 1995; 36:A628

Drugs

Indications